Risankizumab for previously treated moderately to severely active Crohn's disease

NICE has produced a resource impact template that incorporates the following technology appraisals for previously treated moderately to severely active Crohn's disease:

• mirikizumab for previously treated moderately to severely active Crohn's disease (2025) NICE technology appraisal guidance 1080
• upadacitinib for previously treated moderately to severely active Crohn’s disease (2023) NICE technology appraisal guidance 905
• risankizumab for previously treated moderately to severely active Crohn's disease (2023) NICE technology appraisal guidance 888
• ustekinumab for moderately to severely active Crohn’s disease after previous treatment (2017) NICE technology appraisal guidance 456.